Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.40 +0.05 (+3.70%)
At close: Nov 11, 2026 · 4:00 PM EST

Transcode Therapeutics (RNAZ) Total Debt (2026)

Updated

Transcode Therapeutics' Total Debt came in at $652,411 for Q2 2026.

Analysis

Transcode Therapeutics (RNAZ) Total Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 49.50 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 44.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 80.90 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 53.78 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -6.68 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 54.01 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 26.23 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 62.67 Bn
10 Transcode Therapeutics 1.37 Mn -40.52 Mn - 652,411.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 652,411.00
API Access

Transcode Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=RNAZ&period=max&api_key=YOUR_API_KEY